<code id='1FAA854F44'></code><style id='1FAA854F44'></style>
    • <acronym id='1FAA854F44'></acronym>
      <center id='1FAA854F44'><center id='1FAA854F44'><tfoot id='1FAA854F44'></tfoot></center><abbr id='1FAA854F44'><dir id='1FAA854F44'><tfoot id='1FAA854F44'></tfoot><noframes id='1FAA854F44'>

    • <optgroup id='1FAA854F44'><strike id='1FAA854F44'><sup id='1FAA854F44'></sup></strike><code id='1FAA854F44'></code></optgroup>
        1. <b id='1FAA854F44'><label id='1FAA854F44'><select id='1FAA854F44'><dt id='1FAA854F44'><span id='1FAA854F44'></span></dt></select></label></b><u id='1FAA854F44'></u>
          <i id='1FAA854F44'><strike id='1FAA854F44'><tt id='1FAA854F44'><pre id='1FAA854F44'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:explore    - browse:61

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge